PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
32312992-4	2020	Using a function-oriented synthesis approach, we synthesize a series of bryostatin analogs designed to maintain affinity for bryostatin"s target protein kinase C (PKC) while enabling exploration of their divergent biological functions.	Bryostatins	72-82	proline rich transmembrane protein 2	Homo sapiens	145-161
32312992-4	2020	Using a function-oriented synthesis approach, we synthesize a series of bryostatin analogs designed to maintain affinity for bryostatin"s target protein kinase C (PKC) while enabling exploration of their divergent biological functions.	Bryostatins	72-82	proline rich transmembrane protein 2	Homo sapiens	163-166
32312992-5	2020	Our late-stage diversification strategy provides efficient access to a library of bryostatin analogs, which per our design retain affinity for PKC but exhibit variable PKC translocation kinetics.	Bryostatins	82-92	proline rich transmembrane protein 2	Homo sapiens	143-146
32312992-5	2020	Our late-stage diversification strategy provides efficient access to a library of bryostatin analogs, which per our design retain affinity for PKC but exhibit variable PKC translocation kinetics.	Bryostatins	82-92	proline rich transmembrane protein 2	Homo sapiens	168-171
32312992-6	2020	We further demonstrate that select analogs potently increase cell surface expression of CD22, a promising CAR T cell target for the treatment of leukemias, highlighting the clinical potential of bryostatin analogs for enhancing targeted immunotherapies.	Bryostatins	195-205	CD22 molecule	Homo sapiens	88-92
32209043-4	2020	The structure-activity relationship of bryostatins has been well established, with the identification of key pharmacopjoric features important for PKC modulation.	Bryostatins	39-50	protein kinase C, alpha	Mus musculus	147-150
32103135-5	2020	We found bryostatin can target multiple types of protein other than only protein kinase C. Functional network analysis of the target profile and differential expressed genes suggested that bryostatin may activate a few novel pathways such as pyrimidine metabolism, purine metabolism and p53 signaling pathway, besides commonly known pathways DNA replication, cell cycle and so on.	Bryostatins	9-19	tumor protein p53	Homo sapiens	287-290
32103135-5	2020	We found bryostatin can target multiple types of protein other than only protein kinase C. Functional network analysis of the target profile and differential expressed genes suggested that bryostatin may activate a few novel pathways such as pyrimidine metabolism, purine metabolism and p53 signaling pathway, besides commonly known pathways DNA replication, cell cycle and so on.	Bryostatins	189-199	tumor protein p53	Homo sapiens	287-290
32103135-6	2020	The results suggest that bryostatin may reactivate the HIV-latent cells through up-regulation of pyrimidine and purine metabolism or through starting the cell-cycle arrest and apoptosis induced by up-regulation of p53 signaling pathway.	Bryostatins	25-35	tumor protein p53	Homo sapiens	214-217
30366100-11	2019	Bryostatin and both BET inhibitors downregulated the expression of CD279 on CD8+ T cells without affecting their activation.	Bryostatins	0-10	programmed cell death 1	Homo sapiens	67-72
30530975-1	2019	BACKGROUND: Bryostatin-activated PKC epsilon pre-clinically induces synaptogenesis, anti-apoptosis, anti-amyloid-beta oligomers, and anti-hyperphosphorylated tau.	Bryostatins	12-22	amyloid beta precursor protein	Homo sapiens	105-117
30530975-1	2019	BACKGROUND: Bryostatin-activated PKC epsilon pre-clinically induces synaptogenesis, anti-apoptosis, anti-amyloid-beta oligomers, and anti-hyperphosphorylated tau.	Bryostatins	12-22	microtubule associated protein tau	Homo sapiens	158-161
30778080-5	2019	Conversely, PD-1 blockade with the monoclonal antibody pembrolizumab enhances HIV production in combination with the latency reversing agent bryostatin without increasing T cell activation.	Bryostatins	141-151	programmed cell death 1	Homo sapiens	12-16
30366100-11	2019	Bryostatin and both BET inhibitors downregulated the expression of CD279 on CD8+ T cells without affecting their activation.	Bryostatins	0-10	CD8a molecule	Homo sapiens	76-79
30366100-12	2019	Our comparison of LRAs identified differences in cytotoxicity between LRA classes and members within a class and suggests that some LRAs such as bryostatin and BET inhibitors may also downregulate inhibitory receptors on activated HIV-specific CD8+ T cells.	Bryostatins	145-155	CD8a molecule	Homo sapiens	244-247
28482641-3	2017	In close parallel with peak blood levels of bryostatin, an increase of PBMC PKCe was measured (p = 0.0185) within 1 h from the onset of infusion.	Bryostatins	44-54	protein kinase C epsilon	Homo sapiens	76-80
29392180-3	2018	Yet nothing is known about the conformation of bryostatin bound to its protein kinase C (PKC) target in a membrane microenvironment.	Bryostatins	47-57	proline rich transmembrane protein 2	Homo sapiens	71-87
29392180-3	2018	Yet nothing is known about the conformation of bryostatin bound to its protein kinase C (PKC) target in a membrane microenvironment.	Bryostatins	47-57	proline rich transmembrane protein 2	Homo sapiens	89-92
29710707-10	2018	Reduction of PKCe and MnSOD was prevented with the PKCe activator bryostatin in 5-6-month-old Tg2576 AD transgenic mice.	Bryostatins	66-76	protein kinase C, epsilon	Mus musculus	13-17
29710707-10	2018	Reduction of PKCe and MnSOD was prevented with the PKCe activator bryostatin in 5-6-month-old Tg2576 AD transgenic mice.	Bryostatins	66-76	superoxide dismutase 2, mitochondrial	Mus musculus	22-27
29710707-10	2018	Reduction of PKCe and MnSOD was prevented with the PKCe activator bryostatin in 5-6-month-old Tg2576 AD transgenic mice.	Bryostatins	66-76	protein kinase C, epsilon	Mus musculus	51-55
24906106-3	2014	Using a capillary isoelectric focusing immunoassay system, we could visualize a high resolution isoelectric focusing signature of PKCdelta upon stimulation by ligands of the phorbol ester and bryostatin classes.	Bryostatins	192-202	protein kinase C delta	Homo sapiens	130-138
26900625-4	2016	Bryostatin-based therapeutic efforts and even recent anti-CHIKV strategies have centered on modulation of protein kinase C (PKC).	Bryostatins	0-10	proline rich transmembrane protein 2	Homo sapiens	124-127
26900625-5	2016	Intriguingly, while the C ring of bryostatin primarily drives interactions with PKC, A- and B-ring functionality in these analogues has a significant effect on the observed cell-protective activity.	Bryostatins	34-44	proline rich transmembrane protein 2	Homo sapiens	80-83
26199173-0	2015	Bryostatin activates HIV-1 latent expression in human astrocytes through a PKC and NF-kB-dependent mechanism.	Bryostatins	0-10	proline rich transmembrane protein 2	Homo sapiens	75-78
26199173-10	2015	Bryostatin reactivates latent viral infection in the NHA and U87 cells via activation of protein kinase C (PKC)-alpha and -delta, because the PKC inhibitors rottlerin and GF109203X abrogated the bryostatin effect.	Bryostatins	0-10	protein kinase C alpha	Homo sapiens	89-128
26199173-10	2015	Bryostatin reactivates latent viral infection in the NHA and U87 cells via activation of protein kinase C (PKC)-alpha and -delta, because the PKC inhibitors rottlerin and GF109203X abrogated the bryostatin effect.	Bryostatins	0-10	proline rich transmembrane protein 2	Homo sapiens	107-110
26199173-10	2015	Bryostatin reactivates latent viral infection in the NHA and U87 cells via activation of protein kinase C (PKC)-alpha and -delta, because the PKC inhibitors rottlerin and GF109203X abrogated the bryostatin effect.	Bryostatins	195-205	protein kinase C alpha	Homo sapiens	89-128
26199173-12	2015	Moreover, bryostatin strongly stimulated LTR transcription by activating the transcription factor NF-kappaB.	Bryostatins	10-20	nuclear factor kappa B subunit 1	Homo sapiens	98-107
25188731-5	2014	A key difference was the identification of a kinase-controlled inhibitory pathway of Pmp22 transcription revealed by the activity of the Protein kinase C (PKC)-modulator bryostatin.	Bryostatins	170-180	peripheral myelin protein 22	Homo sapiens	85-90
27978828-16	2016	FAK inhibition induced loss of mitochondrial membrane potential, which was counteracted by bryostatin, and increased superoxide and hydrogen peroxide production.	Bryostatins	91-101	PTK2 protein tyrosine kinase 2	Mus musculus	0-3
27978828-17	2016	Bryostatin and HGF reduced the substantial cell death caused by FAK inhibition over a 24 h period.	Bryostatins	0-10	PTK2 protein tyrosine kinase 2	Mus musculus	64-67
27494208-1	2016	As an initial step in designing a simplified bryostatin hybrid molecule, three bryostatin analogues bearing a diacylglycerol lactone-based C-ring, which possessed the requisite pharmacophores for binding to protein kinase C (PKC) together with a modified bryostatin-like A- and B-ring region, were synthesized and evaluated.	Bryostatins	79-89	protein kinase C alpha	Homo sapiens	225-228
27494208-1	2016	As an initial step in designing a simplified bryostatin hybrid molecule, three bryostatin analogues bearing a diacylglycerol lactone-based C-ring, which possessed the requisite pharmacophores for binding to protein kinase C (PKC) together with a modified bryostatin-like A- and B-ring region, were synthesized and evaluated.	Bryostatins	79-89	protein kinase C alpha	Homo sapiens	225-228
26292580-2	2016	Given their potential clinical ramifications, PKC modulators, e.g. phorbol esters and bryostatin, are also of great interest in the drug development.	Bryostatins	86-96	protein kinase C delta	Homo sapiens	46-49
26292580-3	2016	However, structural details on the binding between PKC and its modulators, especially bryostatin - the highly potent and non-tumor promoting activator for PKCs, are still lacking.	Bryostatins	86-96	protein kinase C delta	Homo sapiens	51-54
26292580-7	2016	For the PKC delta-bryostatin complex, hydrogen bonds are formed between the Gly253 backbone carbonyl and the C30 carbomethoxy substituent of the ligand.	Bryostatins	18-28	protein kinase C delta	Homo sapiens	8-17
26189021-2	2015	Bryostatin, a potent protein kinase C (PKC) modulator, has shown promise in treating neurological injury.	Bryostatins	0-10	protein kinase C, alpha	Rattus norvegicus	39-42
26189021-9	2015	Administration of bryostatin also limited BBB disruption and HT and down-regulated MMP-9 expression while up-regulating PKCepsilon expression at 24 h post-MCAO.	Bryostatins	18-28	matrix metallopeptidase 9	Rattus norvegicus	83-88
26189021-10	2015	Bryostatin administration ameliorates BBB disruption and reduces the risk of HT by down-regulating MMP-9 activation and up-regulating PKCepsilon.	Bryostatins	0-10	matrix metallopeptidase 9	Rattus norvegicus	99-104
25710634-0	2015	Toward a biorelevant structure of protein kinase C bound modulators: design, synthesis, and evaluation of labeled bryostatin analogues for analysis with rotational echo double resonance NMR spectroscopy.	Bryostatins	114-124	proline rich transmembrane protein 2	Homo sapiens	34-50
25710634-8	2015	These potent and strategically labeled bryostatin analogues are new structural leads and provide the necessary starting point for projected efforts to determine the PKC-bound conformation of such analogues in a membrane environment, as needed to design new PKC modulators and understand PKC-ligand-membrane structure and dynamics.	Bryostatins	39-49	proline rich transmembrane protein 2	Homo sapiens	165-168
25710634-8	2015	These potent and strategically labeled bryostatin analogues are new structural leads and provide the necessary starting point for projected efforts to determine the PKC-bound conformation of such analogues in a membrane environment, as needed to design new PKC modulators and understand PKC-ligand-membrane structure and dynamics.	Bryostatins	39-49	proline rich transmembrane protein 2	Homo sapiens	257-260
25710634-8	2015	These potent and strategically labeled bryostatin analogues are new structural leads and provide the necessary starting point for projected efforts to determine the PKC-bound conformation of such analogues in a membrane environment, as needed to design new PKC modulators and understand PKC-ligand-membrane structure and dynamics.	Bryostatins	39-49	proline rich transmembrane protein 2	Homo sapiens	257-260
24637095-7	2014	Furthermore, the bryostatin-induced increase of the frequency and amplitude of IPSCs was blocked by methionine enkephalin which selectively suppressed the excitability of interneurons.	Bryostatins	17-27	proenkephalin	Rattus norvegicus	111-121
24637095-8	2014	Pretreatment with RO-32-0432, a relatively specific PKCalpha antagonist, blocked the effect of bryostatin on sIPSCs.	Bryostatins	95-105	protein kinase C, alpha	Rattus norvegicus	52-60
24637095-11	2014	Taken together, these results suggest that bryostatin enhances GABAergic neurotransmission in pyramidal neurons by activating the PKCalpha & epsilon-dependent pathway and by a presynaptic mechanism with excitation of GABAergic interneurons.	Bryostatins	43-53	protein kinase C, alpha	Rattus norvegicus	130-138
24848988-12	2014	Bryostatin treatment also rescued Abeta-mediated inhibition of HuD-NEP mRNA binding, NEP protein expression, and NEP cell membrane translocation.	Bryostatins	0-10	amyloid beta precursor protein	Homo sapiens	34-39
24848988-12	2014	Bryostatin treatment also rescued Abeta-mediated inhibition of HuD-NEP mRNA binding, NEP protein expression, and NEP cell membrane translocation.	Bryostatins	0-10	membrane metalloendopeptidase	Homo sapiens	67-70
24848988-12	2014	Bryostatin treatment also rescued Abeta-mediated inhibition of HuD-NEP mRNA binding, NEP protein expression, and NEP cell membrane translocation.	Bryostatins	0-10	membrane metalloendopeptidase	Homo sapiens	85-88
24848988-12	2014	Bryostatin treatment also rescued Abeta-mediated inhibition of HuD-NEP mRNA binding, NEP protein expression, and NEP cell membrane translocation.	Bryostatins	0-10	membrane metalloendopeptidase	Homo sapiens	85-88
23121542-0	2013	Mechanistic and computational studies of exocyclic stereocontrol in the synthesis of bryostatin-like cis-2,6-disubstituted 4-alkylidenetetrahydropyrans by Prins cyclization.	Bryostatins	85-95	suppressor of cytokine signaling 2	Homo sapiens	101-106
24848988-9	2014	Treatment with bryostatin, a PKCepsilon-selective activator, enhanced NEP association with HuD and increased NEP mRNA stability.	Bryostatins	15-25	protein kinase C epsilon	Homo sapiens	29-39
24848988-9	2014	Treatment with bryostatin, a PKCepsilon-selective activator, enhanced NEP association with HuD and increased NEP mRNA stability.	Bryostatins	15-25	membrane metalloendopeptidase	Homo sapiens	70-73
24848988-9	2014	Treatment with bryostatin, a PKCepsilon-selective activator, enhanced NEP association with HuD and increased NEP mRNA stability.	Bryostatins	15-25	membrane metalloendopeptidase	Homo sapiens	109-112
24672140-0	2013	Lead Diversification through a Prins-Driven Macrocyclization Strategy: Application to C13-Diversified Bryostatin Analogues.	Bryostatins	102-112	homeobox C13	Homo sapiens	86-89
24672140-1	2013	The design, synthesis, and biological evaluation of a novel class of C13-diversified bryostatin analogues are described.	Bryostatins	85-95	homeobox C13	Homo sapiens	69-72
24672140-3	2013	In vitro analysis of selected library members revealed that modification at the C13 position of the bryostatin scaffold can be used as a diversification handle to regulate biological activity.	Bryostatins	100-110	homeobox C13	Homo sapiens	80-83
22832728-8	2012	Finally, compared with the wild type, the 5-HT(1A)-R(-/-) mice harbor significantly less synapses in the hippocampus, but infusion of the PKC-stimulator and Alzheimer drug bryostatin into the 5-HT(1A)-R(-/-) mice to bypass the non-existent 5-HT(1A)-R boosted PSD95 expression and synaptogenesis.	Bryostatins	172-182	5-hydroxytryptamine receptor 1A	Homo sapiens	42-49
22736542-5	2012	Bryostatin, a PKC activator, treatment enhanced their association with HuD and increased these transcripts" stability.	Bryostatins	0-10	proline rich transmembrane protein 2	Homo sapiens	14-17
22736542-6	2012	Bryostatin induced HuD phosphorylation, which was inhibited by Ro 32-0432, a specific PKC inhibitor.	Bryostatins	0-10	proline rich transmembrane protein 2	Homo sapiens	86-89
22736542-8	2012	Furthermore cotreatment of bryostatin and AMI-1, a specific CARM1 inhibitor, potentiated PKC-dependent HuD-mRNA interactions and enhanced dendritic arborization.	Bryostatins	27-37	coactivator associated arginine methyltransferase 1	Homo sapiens	60-65
22736542-8	2012	Furthermore cotreatment of bryostatin and AMI-1, a specific CARM1 inhibitor, potentiated PKC-dependent HuD-mRNA interactions and enhanced dendritic arborization.	Bryostatins	27-37	proline rich transmembrane protein 2	Homo sapiens	89-92
23078780-11	2012	Bryostatin, a PKC modulator and suppressor of CXCR4, conferred neuroprotection against combined insult with HIV-1 and CXCL10.	Bryostatins	0-10	C-X-C motif chemokine ligand 10	Homo sapiens	118-124
23078780-12	2012	Bryostatin also suppressed HIV-1 and CXCL10-induced PBMC chemotaxis.	Bryostatins	0-10	C-X-C motif chemokine ligand 10	Homo sapiens	37-43
23078780-14	2012	CONCLUSION: We have demonstrated induction of CXCL10 and other chemokines/cytokines during HIV-1 infection in the brain, as well as synergism of CXCL10 with HIV-1 in neuronal toxicity, which was dampened by bryostatin.	Bryostatins	207-217	C-X-C motif chemokine ligand 10	Homo sapiens	145-151
22738985-1	2012	Six bryostatins were isolated from Japanese bryozoan by evaluating their binding to the C1B domain of protein kinase Cdelta (PKCdelta).	Bryostatins	4-15	protein kinase C delta	Homo sapiens	102-123
22738985-1	2012	Six bryostatins were isolated from Japanese bryozoan by evaluating their binding to the C1B domain of protein kinase Cdelta (PKCdelta).	Bryostatins	4-15	protein kinase C delta	Homo sapiens	125-133
22308267-0	2012	"Picolog," a synthetically-available bryostatin analog, inhibits growth of MYC-induced lymphoma in vivo.	Bryostatins	37-47	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	75-78
22308267-5	2012	Picolog, compared to bryostatin, exhibited superior growth inhibition of MYC-induced lymphoma in vitro.	Bryostatins	21-31	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	73-76
20585398-0	2010	Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner.	Bryostatins	0-10	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	56-60
21035732-2	2010	Herein, we report the biochemical characterization of BryR, the 3-hydroxy-3-methylglutaryl (HMG)-CoA synthase (HMGS) homolog implicated in beta-branching at C13 and C21 of the core ring system from the bryostatin metabolic pathway (Bry).	Bryostatins	202-212	3-hydroxy-3-methylglutaryl-CoA synthase 2	Homo sapiens	64-109
20585398-4	2010	Bryostatin revealed antiviral activity against R5- and X4-tropic viruses in receptor independent and partly via transient decrease in CD4/CXCR4 expression.	Bryostatins	0-10	CD4 molecule	Homo sapiens	134-137
20585398-4	2010	Bryostatin revealed antiviral activity against R5- and X4-tropic viruses in receptor independent and partly via transient decrease in CD4/CXCR4 expression.	Bryostatins	0-10	C-X-C motif chemokine receptor 4	Homo sapiens	138-143
20585398-5	2010	Further, bryostatin at low nanomolar concentrations robustly reactivated latent viral infection in monocytic and lymphocytic cells via activation of Protein Kinase C (PKC) -alpha and -delta, because PKC inhibitors rottlerin and GF109203X abrogated the bryostatin effect.	Bryostatins	9-19	protein kinase C alpha	Homo sapiens	149-189
20585398-5	2010	Further, bryostatin at low nanomolar concentrations robustly reactivated latent viral infection in monocytic and lymphocytic cells via activation of Protein Kinase C (PKC) -alpha and -delta, because PKC inhibitors rottlerin and GF109203X abrogated the bryostatin effect.	Bryostatins	9-19	protein kinase C alpha	Homo sapiens	167-170
20585398-6	2010	Bryostatin specifically modulated novel PKC (nPKC) involving stress induced AMP Kinase (AMPK) inasmuch as an inhibitor of AMPK, compound C partially ablated the viral reactivation effect.	Bryostatins	0-10	protein kinase C alpha	Homo sapiens	40-43
20585398-6	2010	Bryostatin specifically modulated novel PKC (nPKC) involving stress induced AMP Kinase (AMPK) inasmuch as an inhibitor of AMPK, compound C partially ablated the viral reactivation effect.	Bryostatins	0-10	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	76-86
20585398-6	2010	Bryostatin specifically modulated novel PKC (nPKC) involving stress induced AMP Kinase (AMPK) inasmuch as an inhibitor of AMPK, compound C partially ablated the viral reactivation effect.	Bryostatins	0-10	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	88-92
20585398-6	2010	Bryostatin specifically modulated novel PKC (nPKC) involving stress induced AMP Kinase (AMPK) inasmuch as an inhibitor of AMPK, compound C partially ablated the viral reactivation effect.	Bryostatins	0-10	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	122-126
19850930-4	2009	Unlike PKC activators that bind to the 1,2-diacylglycerol-binding site, such as bryostatin and phorbol esters, which produce prolonged down-regulation, the new activators produced sustained activation of PKC.	Bryostatins	80-90	protein kinase C epsilon	Homo sapiens	204-207
19737143-4	2009	Protein kinase C (PKC) agonists (such as bryostatin) delayed the death of vincristine-treated CLL cells and made them highly immunogenic, with increased stimulatory abilities in mixed lymphocyte responses, production of proinflammatory cytokines, expression of co-stimulatory molecules and activation of c-Jun N-terminal kinase (JNK), p38 and nuclear factor kappa B (NF-kappaB) signalling pathways.	Bryostatins	41-51	mitogen-activated protein kinase 8	Homo sapiens	304-327
19737143-4	2009	Protein kinase C (PKC) agonists (such as bryostatin) delayed the death of vincristine-treated CLL cells and made them highly immunogenic, with increased stimulatory abilities in mixed lymphocyte responses, production of proinflammatory cytokines, expression of co-stimulatory molecules and activation of c-Jun N-terminal kinase (JNK), p38 and nuclear factor kappa B (NF-kappaB) signalling pathways.	Bryostatins	41-51	mitogen-activated protein kinase 8	Homo sapiens	329-332
19737143-4	2009	Protein kinase C (PKC) agonists (such as bryostatin) delayed the death of vincristine-treated CLL cells and made them highly immunogenic, with increased stimulatory abilities in mixed lymphocyte responses, production of proinflammatory cytokines, expression of co-stimulatory molecules and activation of c-Jun N-terminal kinase (JNK), p38 and nuclear factor kappa B (NF-kappaB) signalling pathways.	Bryostatins	41-51	mitogen-activated protein kinase 14	Homo sapiens	335-338
19737143-4	2009	Protein kinase C (PKC) agonists (such as bryostatin) delayed the death of vincristine-treated CLL cells and made them highly immunogenic, with increased stimulatory abilities in mixed lymphocyte responses, production of proinflammatory cytokines, expression of co-stimulatory molecules and activation of c-Jun N-terminal kinase (JNK), p38 and nuclear factor kappa B (NF-kappaB) signalling pathways.	Bryostatins	41-51	nuclear factor kappa B subunit 1	Homo sapiens	343-365
19737143-4	2009	Protein kinase C (PKC) agonists (such as bryostatin) delayed the death of vincristine-treated CLL cells and made them highly immunogenic, with increased stimulatory abilities in mixed lymphocyte responses, production of proinflammatory cytokines, expression of co-stimulatory molecules and activation of c-Jun N-terminal kinase (JNK), p38 and nuclear factor kappa B (NF-kappaB) signalling pathways.	Bryostatins	41-51	nuclear factor kappa B subunit 1	Homo sapiens	367-376
19118090-9	2009	Finally, we found that mutating the STAT3 binding site sequence within the eNOS promoter increased promoter activity in response to shear and that this was no longer inhibited by bryostatin.	Bryostatins	179-189	signal transducer and activator of transcription 3	Homo sapiens	36-41
19233276-4	2009	As reported herein bryostatin and a potent synthetic analog (picolog) are found to cause stimulation of non-amyloidogenic pathways by increasing alpha-secretase activity and thus lowering the amount of toxic Abeta produced.	Bryostatins	19-29	amyloid beta precursor protein	Homo sapiens	208-213
19233276-7	2009	This Biomarker, based on bradykinin-induced differential phosphorylation of Erk1 and Erk2, has been used here to test the therapeutic efficacy both for bryostatin and picolog.	Bryostatins	152-162	kininogen 1	Homo sapiens	25-35
19233276-7	2009	This Biomarker, based on bradykinin-induced differential phosphorylation of Erk1 and Erk2, has been used here to test the therapeutic efficacy both for bryostatin and picolog.	Bryostatins	152-162	mitogen-activated protein kinase 3	Homo sapiens	76-80
19233276-7	2009	This Biomarker, based on bradykinin-induced differential phosphorylation of Erk1 and Erk2, has been used here to test the therapeutic efficacy both for bryostatin and picolog.	Bryostatins	152-162	mitogen-activated protein kinase 1	Homo sapiens	85-89
19118090-9	2009	Finally, we found that mutating the STAT3 binding site sequence within the eNOS promoter increased promoter activity in response to shear and that this was no longer inhibited by bryostatin.	Bryostatins	179-189	nitric oxide synthase 3	Homo sapiens	75-79
19022511-2	2009	The promising anticancer clinical candidates salinosporamide A and bryostatin only hint at the incredible wealth of drug leads hidden just beneath the ocean surface.	Bryostatins	67-77	histidine triad nucleotide binding protein 1	Homo sapiens	83-87
18974109-6	2008	The involvement of bryostatins in the SDF-1/CXCR4 signaling process has never been reported.	Bryostatins	19-30	C-X-C motif chemokine ligand 12	Homo sapiens	38-43
18974109-6	2008	The involvement of bryostatins in the SDF-1/CXCR4 signaling process has never been reported.	Bryostatins	19-30	C-X-C motif chemokine receptor 4	Homo sapiens	44-49
18588309-0	2008	The design, synthesis, and evaluation of C7 diversified bryostatin analogs reveals a hot spot for PKC affinity.	Bryostatins	56-66	proline rich transmembrane protein 2	Homo sapiens	98-101
17003377-7	2007	Conversely, BCR-mediated intracellular Ca2+ release could be inhibited in CLL cells with low levels of active PKCbetaII by pretreatment with the PKC agonist bryostatin.	Bryostatins	157-167	BCR activator of RhoGEF and GTPase	Homo sapiens	12-15
17003377-7	2007	Conversely, BCR-mediated intracellular Ca2+ release could be inhibited in CLL cells with low levels of active PKCbetaII by pretreatment with the PKC agonist bryostatin.	Bryostatins	157-167	protein kinase C beta	Homo sapiens	110-113
11172674-1	2001	The natural products teleocidins, phorbol esters, asplysiatoxin, ingenol esters, and bryostatins are all potent protein kinase C (PKC) activators.	Bryostatins	85-96	proline rich transmembrane protein 2	Homo sapiens	112-128
15624982-0	2005	Late-stage intermolecular CH activation for lead diversification: a highly chemoselective oxyfunctionalization of the C-9 position of potent bryostatin analogues.	Bryostatins	141-151	complement C9	Homo sapiens	118-121
15624982-1	2005	Treatment of highly potent and densely functionalized bryostatin analogue 1 with dimethyldioxirane afforded the C-9 hydroxylated hemiketal 2 via oxyfunctionalization of the C9-CH bond, one of 12 CH bonds geminal to an oxygen substituent in 1.	Bryostatins	54-64	complement C9	Homo sapiens	112-115
15624982-2	2005	When bryostatin analogue 3 was subjected to identical conditions, oxidation of a C-26 secondary hydroxyl group was found to compete with C-9 hydroxylation.	Bryostatins	5-15	complement C9	Homo sapiens	137-140
15070901-4	2004	Differentiation-inducing agents (phorbol ester, bryostatin) conveyed THP-1 cells with the ability to up-regulate DC-SIGN mRNA levels and cell surface expression in response to interleukin-4 (IL-4) or IL-13.	Bryostatins	48-58	CD209 molecule	Homo sapiens	113-120
15070901-4	2004	Differentiation-inducing agents (phorbol ester, bryostatin) conveyed THP-1 cells with the ability to up-regulate DC-SIGN mRNA levels and cell surface expression in response to interleukin-4 (IL-4) or IL-13.	Bryostatins	48-58	interleukin 4	Homo sapiens	176-189
15070901-4	2004	Differentiation-inducing agents (phorbol ester, bryostatin) conveyed THP-1 cells with the ability to up-regulate DC-SIGN mRNA levels and cell surface expression in response to interleukin-4 (IL-4) or IL-13.	Bryostatins	48-58	interleukin 4	Homo sapiens	191-195
15070901-4	2004	Differentiation-inducing agents (phorbol ester, bryostatin) conveyed THP-1 cells with the ability to up-regulate DC-SIGN mRNA levels and cell surface expression in response to interleukin-4 (IL-4) or IL-13.	Bryostatins	48-58	interleukin 13	Homo sapiens	200-205
15291360-0	2004	Bryostatin induces protein kinase C modulation, Mcl-1 up-regulation and phosphorylation of Bcl-2 resulting in cellular differentiation and resistance to drug-induced apoptosis in B-cell chronic lymphocytic leukemia cells.	Bryostatins	0-10	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	48-53
15291360-0	2004	Bryostatin induces protein kinase C modulation, Mcl-1 up-regulation and phosphorylation of Bcl-2 resulting in cellular differentiation and resistance to drug-induced apoptosis in B-cell chronic lymphocytic leukemia cells.	Bryostatins	0-10	BCL2 apoptosis regulator	Homo sapiens	91-96
15291360-2	2004	In this study, we demonstrated Bryostatin-induced differentiation in B-cell chronic lymphocytic leukemia (B-CLL) cells, characterized by an increase in cell size and a marked up-regulation of CD11c expression.	Bryostatins	31-41	integrin subunit alpha X	Homo sapiens	192-197
15291360-3	2004	The specific inhibitors of the extracellular signal-regulated kinase (ERK) and protein kinase C pathways, PD98059 and GF 109203X respectively, each completely blocked Bryostatin-induced differentiation of B-CLL cells, suggesting that activation of the ERK pathway plays a direct role in this process in a PKC-dependent manner.	Bryostatins	167-177	mitogen-activated protein kinase 1	Homo sapiens	31-68
15291360-3	2004	The specific inhibitors of the extracellular signal-regulated kinase (ERK) and protein kinase C pathways, PD98059 and GF 109203X respectively, each completely blocked Bryostatin-induced differentiation of B-CLL cells, suggesting that activation of the ERK pathway plays a direct role in this process in a PKC-dependent manner.	Bryostatins	167-177	mitogen-activated protein kinase 1	Homo sapiens	70-73
15291360-3	2004	The specific inhibitors of the extracellular signal-regulated kinase (ERK) and protein kinase C pathways, PD98059 and GF 109203X respectively, each completely blocked Bryostatin-induced differentiation of B-CLL cells, suggesting that activation of the ERK pathway plays a direct role in this process in a PKC-dependent manner.	Bryostatins	167-177	mitogen-activated protein kinase 1	Homo sapiens	252-255
15291360-4	2004	Furthermore, Bryostatin reduced both spontaneous and drug-induced apoptosis with chlorambucil, fludarabine and 2-chloro-2"-deoxyadenosine (2-Cda) in B-CLL cells.	Bryostatins	13-23	cytidine deaminase	Homo sapiens	141-144
14527959-5	2003	We found that cIAP-2 mRNA levels were markedly increased in human colon cancer cells by treatment with the phorbol ester, phorbol-12-myristate-13-acetate (PMA), or bryostatin 1.	Bryostatins	164-174	baculoviral IAP repeat containing 3	Homo sapiens	14-20
14581379-5	2003	Bryostatin (1-10 nM) induced COX-2 mRNA, COX-2 protein, and prostaglandin biosynthesis.	Bryostatins	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	29-34
14581379-5	2003	Bryostatin (1-10 nM) induced COX-2 mRNA, COX-2 protein, and prostaglandin biosynthesis.	Bryostatins	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	41-46
12759450-6	2003	Selective activation of PKC delta by bryostatin also activated NF-kappa B, as evidenced by p65 RelA and p50 NF-kappa B1 binding to DNA, NF-kappa B trans-activation, and I kappa B degradation.	Bryostatins	37-47	protein kinase C delta	Homo sapiens	24-33
12759450-6	2003	Selective activation of PKC delta by bryostatin also activated NF-kappa B, as evidenced by p65 RelA and p50 NF-kappa B1 binding to DNA, NF-kappa B trans-activation, and I kappa B degradation.	Bryostatins	37-47	nuclear factor kappa B subunit 1	Homo sapiens	63-73
12759450-6	2003	Selective activation of PKC delta by bryostatin also activated NF-kappa B, as evidenced by p65 RelA and p50 NF-kappa B1 binding to DNA, NF-kappa B trans-activation, and I kappa B degradation.	Bryostatins	37-47	RELA proto-oncogene, NF-kB subunit	Homo sapiens	91-94
12759450-6	2003	Selective activation of PKC delta by bryostatin also activated NF-kappa B, as evidenced by p65 RelA and p50 NF-kappa B1 binding to DNA, NF-kappa B trans-activation, and I kappa B degradation.	Bryostatins	37-47	nuclear factor kappa B subunit 1	Homo sapiens	104-107
12759450-6	2003	Selective activation of PKC delta by bryostatin also activated NF-kappa B, as evidenced by p65 RelA and p50 NF-kappa B1 binding to DNA, NF-kappa B trans-activation, and I kappa B degradation.	Bryostatins	37-47	nuclear factor kappa B subunit 1	Homo sapiens	108-118
16623578-0	2006	Design, synthesis, and biological evaluation of a potent, PKC selective, B-ring analog of bryostatin.	Bryostatins	90-100	proline rich transmembrane protein 2	Homo sapiens	58-61
16623578-1	2006	[structure: see text] The first member of a new class of five-membered B-ring analogs of bryostatin has been synthesized and tested for its ability to bind and translocate protein kinase C (PKC).	Bryostatins	89-99	proline rich transmembrane protein 2	Homo sapiens	172-188
16623578-1	2006	[structure: see text] The first member of a new class of five-membered B-ring analogs of bryostatin has been synthesized and tested for its ability to bind and translocate protein kinase C (PKC).	Bryostatins	89-99	proline rich transmembrane protein 2	Homo sapiens	190-193
15588099-0	2004	Synthetic bryostatin analogues activate the RasGRP1 signaling pathway.	Bryostatins	10-20	RAS guanyl releasing protein 1	Mus musculus	44-51
11172674-1	2001	The natural products teleocidins, phorbol esters, asplysiatoxin, ingenol esters, and bryostatins are all potent protein kinase C (PKC) activators.	Bryostatins	85-96	proline rich transmembrane protein 2	Homo sapiens	130-133
11190577-8	2001	The situation is complicated by the facts that bryostatin leads to the activation of PKC and later to a downmodulation and that the PKC inhibitors available to date are not specific for one PKC isoenzyme.	Bryostatins	47-57	protein kinase C alpha	Homo sapiens	85-88
11190577-10	2001	Despite these problems, PKC modulators such as miltefosine, bryostatin, safingol, CGP41251 and UCN-01 are used in the clinic or are in clinical evaluation.	Bryostatins	60-70	protein kinase C alpha	Homo sapiens	24-27
10779365-11	2000	RasGRP thus provides a direct link between diacylglycerol generation or phorbol ester/bryostatin treatment and Ras activation.	Bryostatins	86-96	RAS guanyl releasing protein 1	Homo sapiens	0-6
11057740-2	2000	A dose of 2 Gy IR was selected for further analyses to determine if subsequent exposure to 10nM bryostatin- would overcome the resistance to IR-induced apoptosis conferred by Bcl-2 over expression.	Bryostatins	96-106	BCL2 apoptosis regulator	Homo sapiens	175-180
10988359-5	2000	Mouse mammary tumor 4TO7-IL-2-primed lymph node cells exposed ex vivo to bryostatin upregulated CD25 expression but lost the ability to secrete IL-2.	Bryostatins	73-83	interleukin 2	Mus musculus	25-29
10988359-5	2000	Mouse mammary tumor 4TO7-IL-2-primed lymph node cells exposed ex vivo to bryostatin upregulated CD25 expression but lost the ability to secrete IL-2.	Bryostatins	73-83	interleukin 2 receptor, alpha chain	Mus musculus	96-100
10988359-6	2000	Most of these cells died by apoptosis unless IL-2 was provided for the duration of bryostatin treatment.	Bryostatins	83-93	interleukin 2	Mus musculus	45-49
10988359-8	2000	Within particular Vbeta clones, only CD25(+) T cells survived exposure to bryostatin and IL-2.	Bryostatins	74-84	interleukin 2 receptor, alpha chain	Mus musculus	37-41
10988359-10	2000	These results indicate that activation of T cells with bryostatin should be carried out under protection of exogenous IL-2 to ensure survival and expansion of T cells that may exhibit anti-tumor activity.	Bryostatins	55-65	interleukin 2	Mus musculus	118-122
11139839-8	1999	New agents such as the staurosporine analogue UCN-01 and bryostatin are thought to affect apoptosis induction by altering BCL-2 phosphorylation.	Bryostatins	57-67	BCL2 apoptosis regulator	Homo sapiens	122-127
10574959-2	1999	Here we demonstrate that two potent activators of PKC, 12-O-tetradecanoylphorbol-13-acetate and bryostatin, both stimulate phosphorylation of Bad at Ser(112), a site known to regulate apoptotic cell death by interleukin-3.	Bryostatins	96-106	interleukin 3	Homo sapiens	208-221
9880547-8	1999	These findings suggest a role for mitogen-activated protein kinase in the degradation of the DNA binding-impaired form of p53 protein and in the bryostatin-induced differentiation observed in this cell line.	Bryostatins	145-155	tumor protein p53	Homo sapiens	122-125
10520003-4	1999	Apoptosis resistance was associated with CD40L- and Bryostatin-induced elevations in the anti-apoptotic Bcl-2 family protein Mcl-1.	Bryostatins	52-62	BCL2 apoptosis regulator	Homo sapiens	104-109
10520003-4	1999	Apoptosis resistance was associated with CD40L- and Bryostatin-induced elevations in the anti-apoptotic Bcl-2 family protein Mcl-1.	Bryostatins	52-62	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	125-130
10520003-6	1999	CD40L stimulated increases in the surface expression of CD40, CD54, CD69, CD70, CD80 and CD95, whereas Bryostatin induced expression of CD40, CD54, CD69 and CD95 but not the co-stimulatory molecules CD70 and CD80.	Bryostatins	103-113	intercellular adhesion molecule 1	Homo sapiens	142-146
10520003-6	1999	CD40L stimulated increases in the surface expression of CD40, CD54, CD69, CD70, CD80 and CD95, whereas Bryostatin induced expression of CD40, CD54, CD69 and CD95 but not the co-stimulatory molecules CD70 and CD80.	Bryostatins	103-113	CD69 molecule	Homo sapiens	148-152
10520003-6	1999	CD40L stimulated increases in the surface expression of CD40, CD54, CD69, CD70, CD80 and CD95, whereas Bryostatin induced expression of CD40, CD54, CD69 and CD95 but not the co-stimulatory molecules CD70 and CD80.	Bryostatins	103-113	Fas cell surface death receptor	Homo sapiens	157-161
10520003-6	1999	CD40L stimulated increases in the surface expression of CD40, CD54, CD69, CD70, CD80 and CD95, whereas Bryostatin induced expression of CD40, CD54, CD69 and CD95 but not the co-stimulatory molecules CD70 and CD80.	Bryostatins	103-113	CD70 molecule	Homo sapiens	199-203
10520003-6	1999	CD40L stimulated increases in the surface expression of CD40, CD54, CD69, CD70, CD80 and CD95, whereas Bryostatin induced expression of CD40, CD54, CD69 and CD95 but not the co-stimulatory molecules CD70 and CD80.	Bryostatins	103-113	CD80 molecule	Homo sapiens	208-212
10520003-8	1999	This Fas-resistance was associated with increased expression of the Fas-antagonist Flip in CD40L-treated, and with elevations in the caspase inhibitor XIAP in Bryostatin-treated B-CLLs.	Bryostatins	159-169	X-linked inhibitor of apoptosis	Homo sapiens	151-155
10049062-0	1999	Role of TNF alpha in bryostatin-induced inhibition of human hematopoiesis.	Bryostatins	21-31	tumor necrosis factor	Homo sapiens	8-17
9685375-8	1998	A cellular assay for PKC betaII function was devised based on the finding that PKC betaII selectively translocates to the nucleus and phosphorylates nuclear lamin B in response to the PKC activator bryostatin.	Bryostatins	198-208	protein kinase C alpha	Homo sapiens	21-24
10197446-1	1999	The novel mouse serine-threonine kinase protein kinase D (PKD) is activated in intact Swiss 3T3 cells stimulated by phorbol esters, cell permeant diacylglycerols, bryostatin, neuropeptides and growth factors via a phosphorylation-dependent mechanism requiring protein kinase C (PKC) activity.	Bryostatins	163-173	protein kinase D1	Mus musculus	40-56
10197446-1	1999	The novel mouse serine-threonine kinase protein kinase D (PKD) is activated in intact Swiss 3T3 cells stimulated by phorbol esters, cell permeant diacylglycerols, bryostatin, neuropeptides and growth factors via a phosphorylation-dependent mechanism requiring protein kinase C (PKC) activity.	Bryostatins	163-173	protein kinase D1	Mus musculus	58-61
9287350-4	1997	TPA, a differentiation inducer, caused sustained activation of ERK (>24 h), whereas bryostatin, a differentiation blocker, only transiently activated ERK ( approximately 6 h) and attenuated the activation of ERK by TPA.	Bryostatins	87-97	mitogen-activated protein kinase 1	Homo sapiens	153-156
9487144-3	1998	We examined involvement of PLD and PKC in the hydrolysis and resynthesis of PtdCho and phosphatidylethanolamine stimulated by beta-TPA, bryostatin (a non-phorbol PKC activator) and oleic acid (18:1n-9) in the four cell lines.	Bryostatins	136-146	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	27-30
9487144-4	1998	beta-TPA or bryostatin produced similar enhancement of [3H]Cho incorporation, loss of stimulated synthesis after down regulation of PKC, and activation of PLD.	Bryostatins	12-22	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	155-158
9287350-4	1997	TPA, a differentiation inducer, caused sustained activation of ERK (>24 h), whereas bryostatin, a differentiation blocker, only transiently activated ERK ( approximately 6 h) and attenuated the activation of ERK by TPA.	Bryostatins	87-97	mitogen-activated protein kinase 1	Homo sapiens	153-156
8895748-9	1996	Blocking protein kinase C function in v-ras(Ha)-keratinocytes with bryostatin restored RARalpha protein to near normal levels, reflecting the involvement of protein kinase C in RARalpha regulation.	Bryostatins	67-77	retinoic acid receptor, alpha	Mus musculus	87-95
9225005-11	1997	The results show that tyrosine phosphorylation and the association of p36-38 with Lck are differentially affected by bryostatin and PMA and suggest that PKC regulates the interaction of potential signaling molecules with Lck, thereby regulating biochemical events that are relevant to T cell mitogenesis and/or transformation.	Bryostatins	117-127	annexin A2	Homo sapiens	70-73
9225005-11	1997	The results show that tyrosine phosphorylation and the association of p36-38 with Lck are differentially affected by bryostatin and PMA and suggest that PKC regulates the interaction of potential signaling molecules with Lck, thereby regulating biochemical events that are relevant to T cell mitogenesis and/or transformation.	Bryostatins	117-127	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	82-85
9225005-11	1997	The results show that tyrosine phosphorylation and the association of p36-38 with Lck are differentially affected by bryostatin and PMA and suggest that PKC regulates the interaction of potential signaling molecules with Lck, thereby regulating biochemical events that are relevant to T cell mitogenesis and/or transformation.	Bryostatins	117-127	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	221-224
9225005-3	1997	We found that the PKC activator, bryostatin, like PMA, induced the conversion of p56lck to a slower migrating form with an apparent molecular mass of 60 kDa.	Bryostatins	33-43	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	81-87
9225005-7	1997	To test whether serine phosphorylation of Lck may affect its ability to bind tyrosine phosphoproteins, we compared Lck immunoprecipitates from PMA- and bryostatin-treated T cells.	Bryostatins	152-162	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	42-45
9225005-9	1997	A p36-38 from PMA- but not bryostatin-treated cells also interacted with an Lck-SH2 fusion protein, suggesting differential regulation of p36-38 by PMA and bryostatin.	Bryostatins	156-166	annexin A2	Homo sapiens	2-5
9225005-9	1997	A p36-38 from PMA- but not bryostatin-treated cells also interacted with an Lck-SH2 fusion protein, suggesting differential regulation of p36-38 by PMA and bryostatin.	Bryostatins	156-166	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	76-79
9225005-9	1997	A p36-38 from PMA- but not bryostatin-treated cells also interacted with an Lck-SH2 fusion protein, suggesting differential regulation of p36-38 by PMA and bryostatin.	Bryostatins	156-166	annexin A2	Homo sapiens	138-141
8952699-5	1996	Expression of this unusual AR isoform was inhibited by protein kinase C (PKC) inhibitors such as bryostatin or H-7.	Bryostatins	97-107	amphiregulin	Homo sapiens	27-29
8895748-9	1996	Blocking protein kinase C function in v-ras(Ha)-keratinocytes with bryostatin restored RARalpha protein to near normal levels, reflecting the involvement of protein kinase C in RARalpha regulation.	Bryostatins	67-77	retinoic acid receptor, alpha	Mus musculus	177-185
8568921-1	1995	The effects of a series of protein kinase inhibitors on nerve growth factor (NGF)-dependent and NGF-independent neurite outgrowth in PC12 cells have established an ordered relationship among those protein kinases sensitive to down regulation by bryostatin, stimulation by staurosporine, inhibition by sphingosine, or inhibition by 6-thioguanine (6-TG).	Bryostatins	245-255	nerve growth factor	Rattus norvegicus	56-75
8870649-4	1996	c-myc, which was induced strongly in response to PMA treatment, was only marginally up-regulated by bryostatin.	Bryostatins	100-110	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	0-5
8870649-5	1996	In addition, bryostatin selectively inhibited the magnitude of PMA-responsive induction of c-myc, to a degree commensurate with its antagonistic effects seen at the biological level.	Bryostatins	13-23	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	91-96
8870649-6	1996	Finally, an anti-sense oligonucleotide blockade of c-myc inhibited PMA-induced proliferation but not the differentiation of BCLL cells, implicating this nuclear oncogene as an important determinant distinguishing PMA from bryostatin-coupled biological responses and also as a candidate third-messenger effector target for the anti-tumour effects of bryostatin.	Bryostatins	222-232	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	51-56
8870649-6	1996	Finally, an anti-sense oligonucleotide blockade of c-myc inhibited PMA-induced proliferation but not the differentiation of BCLL cells, implicating this nuclear oncogene as an important determinant distinguishing PMA from bryostatin-coupled biological responses and also as a candidate third-messenger effector target for the anti-tumour effects of bryostatin.	Bryostatins	349-359	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	51-56
8633191-4	1996	The expression of the IL-2R by lymphocytes was also resistant to NDGA concentrations that effectively blocked the mitogenic effects of TPA or bryostatin, but could be inhibited by higher concentrations of NDGA (IC50 = 8 microM).	Bryostatins	142-152	interleukin 2 receptor subunit alpha	Homo sapiens	22-27
7559663-12	1995	The effects of TPA appear to be mediated by activation of protein kinase C since the protein kinase C inhibitors, H-7 and bryostatin, block the effects of TPA on estradiol induction of progesterone receptor.	Bryostatins	122-132	progesterone receptor	Homo sapiens	185-206
8568921-7	1995	In contrast, low concentrations of phorbol myristoyl acetate (PMA) or bryostatin, which activate protein kinase C activity, enhanced the staurosporine- or NGF-induced neurite extension.	Bryostatins	70-80	nerve growth factor	Rattus norvegicus	155-158
8681440-8	1996	PKC alpha, epsilon and delta, but not PKC eta and zeta, were down-regulated by treating both cell types with bryostatin; pre-treatment of cells with bryostatin inhibited stsp-induced protein cross-linking and marker expression, suggesting a necessity for the alpha, delta and/or epsilon isoforms in stsp-induced differentiation.	Bryostatins	109-119	protein kinase C, alpha	Mus musculus	0-28
8778030-8	1996	(c) Non-motile lymphocytes were chronically treated with the PKC activator bryostatin and the time courses of induction of motility and downregulation of PKC isotypes were compared.	Bryostatins	75-85	proline rich transmembrane protein 2	Homo sapiens	61-64
8568921-1	1995	The effects of a series of protein kinase inhibitors on nerve growth factor (NGF)-dependent and NGF-independent neurite outgrowth in PC12 cells have established an ordered relationship among those protein kinases sensitive to down regulation by bryostatin, stimulation by staurosporine, inhibition by sphingosine, or inhibition by 6-thioguanine (6-TG).	Bryostatins	245-255	nerve growth factor	Rattus norvegicus	77-80
8568921-1	1995	The effects of a series of protein kinase inhibitors on nerve growth factor (NGF)-dependent and NGF-independent neurite outgrowth in PC12 cells have established an ordered relationship among those protein kinases sensitive to down regulation by bryostatin, stimulation by staurosporine, inhibition by sphingosine, or inhibition by 6-thioguanine (6-TG).	Bryostatins	245-255	nerve growth factor	Rattus norvegicus	96-99
8568921-4	1995	Down regulation of protein kinase C by bryostatin chronic treatment, which inhibits NGF- and bFGF-induced neuritogenesis (Singh et al.	Bryostatins	39-49	nerve growth factor	Rattus norvegicus	84-87
8568921-4	1995	Down regulation of protein kinase C by bryostatin chronic treatment, which inhibits NGF- and bFGF-induced neuritogenesis (Singh et al.	Bryostatins	39-49	fibroblast growth factor 2	Rattus norvegicus	93-97
7870033-5	1995	After translocation, PKC-alpha, -delta, -eta, and -epsilon were down-regulated; the down-regulation of PKC-epsilon contrasts with its retention after phorbol-12-myristate-13-acetate or bryostatin treatment.	Bryostatins	185-195	protein kinase C, alpha	Mus musculus	21-58
7628546-2	1995	All PKC isoenzymes except PKC zeta are down-regulated by TPA as well as by bryostatin.	Bryostatins	75-85	protein kinase C alpha	Homo sapiens	4-7
7628546-2	1995	All PKC isoenzymes except PKC zeta are down-regulated by TPA as well as by bryostatin.	Bryostatins	75-85	protein kinase C zeta	Homo sapiens	26-34
7628546-3	1995	However, with PKC delta, bryostatin but not TPA was found to be much less effective at high concentrations than at low ones.	Bryostatins	25-35	protein kinase C delta	Homo sapiens	14-23
7649107-6	1995	The PKC-modulating drugs, bryostatin and H-7, and antiestrogens (ICI 164,384 and 4-hydroxytamoxifen) interfere with AR induction by TPA and estrogen, respectively.	Bryostatins	26-36	amphiregulin	Homo sapiens	116-118
7870033-5	1995	After translocation, PKC-alpha, -delta, -eta, and -epsilon were down-regulated; the down-regulation of PKC-epsilon contrasts with its retention after phorbol-12-myristate-13-acetate or bryostatin treatment.	Bryostatins	185-195	protein kinase C, epsilon	Mus musculus	103-114
7987836-5	1994	Pretreatment of v-rasHa keratinocytes with bryostatin to block PKC function restored Ca(2+)-mediated expression of K1 and K10 and blocked abnormal expression of K8, suggesting that these responses are mediated by the PKC pathway.	Bryostatins	43-53	protein kinase C, alpha	Mus musculus	63-66
7987836-5	1994	Pretreatment of v-rasHa keratinocytes with bryostatin to block PKC function restored Ca(2+)-mediated expression of K1 and K10 and blocked abnormal expression of K8, suggesting that these responses are mediated by the PKC pathway.	Bryostatins	43-53	keratin 1	Mus musculus	115-125
7987836-5	1994	Pretreatment of v-rasHa keratinocytes with bryostatin to block PKC function restored Ca(2+)-mediated expression of K1 and K10 and blocked abnormal expression of K8, suggesting that these responses are mediated by the PKC pathway.	Bryostatins	43-53	protein kinase C, alpha	Mus musculus	217-220
7987836-6	1994	Furthermore, expression of K1 is restored at bryostatin doses which specifically down-modulate PKC-alpha, the only Ca(2+)-dependent PKC isozyme detected in cultured keratinocytes.	Bryostatins	45-55	protein kinase C, alpha	Mus musculus	95-104
7987836-6	1994	Furthermore, expression of K1 is restored at bryostatin doses which specifically down-modulate PKC-alpha, the only Ca(2+)-dependent PKC isozyme detected in cultured keratinocytes.	Bryostatins	45-55	protein kinase C, alpha	Mus musculus	95-98
7987836-8	1994	Pretreatment of v-rasHa keratinocytes with bryostatin blocked expression of late markers in these cells, and this response was correlated with down-regulation of PKC-alpha.	Bryostatins	43-53	protein kinase C, alpha	Mus musculus	162-171
8286384-8	1994	264, 3538-3544], chronic (24 h) treatment with bryostatin blocked the formation of neurites in response to NGF or basic fibroblast-derived growth factor stimulation, but, like PMA, bryostatin did not block the induction of c-fos or c-jun protooncogenes by NGF.	Bryostatins	47-57	nerve growth factor	Rattus norvegicus	107-110
8087865-4	1994	Nevertheless, bryostatin synergizes with suboptimal doses of various T cell mitogens operating via a Ca(2+)-dependent signaling pathway to induce a strong IL-2-dependent proliferative response.	Bryostatins	14-24	interleukin 2	Homo sapiens	155-159
8087865-6	1994	The results suggest that transient activation of cPKC by bryostatin induces some irreversible biochemical events that, by themselves, are not sufficient for the induction of cell proliferation, but that can be complemented by a Ca(2+)-mediated signal(s) leading to IL-2-dependent T cell proliferation.	Bryostatins	57-67	interleukin 2	Homo sapiens	265-269
8087865-7	1994	In contrast, PMA-induced IL-2-independent proliferation of human T cells appears to be dependent on the continuous presence of cPKC (that may mediate some critical events at late stages of the response) and, therefore, is inhibited by bryostatin, that induces a rapid degradation of potentially active cPKC.	Bryostatins	235-245	interleukin 2	Homo sapiens	25-29
7516899-3	1994	The tyrosine phosphorylation of PKC delta is restricted to the activated state of the enzyme, i.e. it occurs only in the presence of an activator, such as TPA or bryostatin.	Bryostatins	162-172	protein kinase C delta	Homo sapiens	32-41
7908680-7	1994	Furthermore, the accumulation of TGK mRNA in keratinocytes treated with TPA or Ca++ is blocked in cells treated with the PKC inhibitor GF 109203X or bryostatin.	Bryostatins	149-159	transglutaminase 1, K polypeptide	Mus musculus	33-36
7954524-3	1994	After Bryostatin administration both LAK generation and proliferation were enhanced when patients" PBMC were stimulated with IL-2 in vitro.	Bryostatins	6-16	interleukin 2	Homo sapiens	125-129
7954524-4	1994	However, when normal donors" PBMC were cultured in vitro in the presence Bryostatin and IL-2, LAK induction was inhibited while IL-2-driven proliferation was increased.	Bryostatins	73-83	interleukin 2	Homo sapiens	128-132
7954524-7	1994	Bryostatin in vitro was found to increase expression of IL-2 receptors on CD4+, CD8+ and CD56+ cells and augment the proportion of CD8+ cells in conjunction with IL-2.	Bryostatins	0-10	interleukin 2	Homo sapiens	56-60
7954524-7	1994	Bryostatin in vitro was found to increase expression of IL-2 receptors on CD4+, CD8+ and CD56+ cells and augment the proportion of CD8+ cells in conjunction with IL-2.	Bryostatins	0-10	CD4 molecule	Homo sapiens	74-77
7954524-7	1994	Bryostatin in vitro was found to increase expression of IL-2 receptors on CD4+, CD8+ and CD56+ cells and augment the proportion of CD8+ cells in conjunction with IL-2.	Bryostatins	0-10	CD8a molecule	Homo sapiens	80-83
7954524-7	1994	Bryostatin in vitro was found to increase expression of IL-2 receptors on CD4+, CD8+ and CD56+ cells and augment the proportion of CD8+ cells in conjunction with IL-2.	Bryostatins	0-10	CD8a molecule	Homo sapiens	131-134
7954524-7	1994	Bryostatin in vitro was found to increase expression of IL-2 receptors on CD4+, CD8+ and CD56+ cells and augment the proportion of CD8+ cells in conjunction with IL-2.	Bryostatins	0-10	interleukin 2	Homo sapiens	162-166
7954524-8	1994	We conclude that Bryostatin in combination with IL-2 in vitro enhances proliferation and IL-2 receptor expression on lymphocytes, favouring CD8+ cells while suppressing the generation of LAK activity.	Bryostatins	17-27	interleukin 2 receptor subunit beta	Homo sapiens	89-102
7954524-8	1994	We conclude that Bryostatin in combination with IL-2 in vitro enhances proliferation and IL-2 receptor expression on lymphocytes, favouring CD8+ cells while suppressing the generation of LAK activity.	Bryostatins	17-27	CD8a molecule	Homo sapiens	140-143
7954524-9	1994	Intravenous administration of Bryostatin increases the potential of IL-2 to induce proliferation and LAK activity in lymphocytes which, taken together with its putative direct antitumour effect, makes Bryostatin an interesting candidate for clinical trials in combination with IL-2.	Bryostatins	30-40	interleukin 2	Homo sapiens	68-72
7954524-9	1994	Intravenous administration of Bryostatin increases the potential of IL-2 to induce proliferation and LAK activity in lymphocytes which, taken together with its putative direct antitumour effect, makes Bryostatin an interesting candidate for clinical trials in combination with IL-2.	Bryostatins	30-40	interleukin 2	Homo sapiens	277-281
7954524-9	1994	Intravenous administration of Bryostatin increases the potential of IL-2 to induce proliferation and LAK activity in lymphocytes which, taken together with its putative direct antitumour effect, makes Bryostatin an interesting candidate for clinical trials in combination with IL-2.	Bryostatins	201-211	interleukin 2	Homo sapiens	68-72
8078499-1	1994	In this study we explored the pattern of protein kinase C (PKC) isozyme selectivity of the bryostatins, a unique class of PKC activators that induce only a subset of the typical phorbol ester responses and antagonize those phorbol ester-mediated responses that they themselves fail to induce.	Bryostatins	91-102	protein kinase C alpha	Homo sapiens	59-62
8078499-1	1994	In this study we explored the pattern of protein kinase C (PKC) isozyme selectivity of the bryostatins, a unique class of PKC activators that induce only a subset of the typical phorbol ester responses and antagonize those phorbol ester-mediated responses that they themselves fail to induce.	Bryostatins	91-102	protein kinase C alpha	Homo sapiens	122-125
8112895-12	1994	A549 cells, in which PKC was depleted by exposure to phorbol ester for 9 weeks, were resistant towards bryostatin-induced inhibition of DNA synthesis.	Bryostatins	103-113	protein kinase C alpha	Homo sapiens	21-24
8112895-13	1994	The results suggest that the susceptibility of adenocarcinoma cells towards bryostatin-induced growth delay are determined by cellular levels of PKCs-alpha and/or -epsilon.	Bryostatins	76-86	protein kinase C alpha	Homo sapiens	145-171
8286384-8	1994	264, 3538-3544], chronic (24 h) treatment with bryostatin blocked the formation of neurites in response to NGF or basic fibroblast-derived growth factor stimulation, but, like PMA, bryostatin did not block the induction of c-fos or c-jun protooncogenes by NGF.	Bryostatins	47-57	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	223-228
8286384-8	1994	264, 3538-3544], chronic (24 h) treatment with bryostatin blocked the formation of neurites in response to NGF or basic fibroblast-derived growth factor stimulation, but, like PMA, bryostatin did not block the induction of c-fos or c-jun protooncogenes by NGF.	Bryostatins	47-57	nerve growth factor	Rattus norvegicus	256-259
8449916-0	1993	Protein kinase C activation without membrane contact in platelets stimulated by bryostatin.	Bryostatins	80-90	proline rich transmembrane protein 2	Homo sapiens	0-16
8449916-5	1993	In a cell-free assay, bryostatin-1 activated PKC purified from platelets if the membrane-derived lipid phosphatidyl serine was present; however, if 12(S)-hydroxy-5,8,10,14-eicosatetraenoic acid or arachidonic acid, two lipid products formed in the cytoplasm of activated platelets, were present, no membrane-derived lipids were required for bryostatin-induced PKC activation.	Bryostatins	22-32	proline rich transmembrane protein 2	Homo sapiens	45-48
8449916-5	1993	In a cell-free assay, bryostatin-1 activated PKC purified from platelets if the membrane-derived lipid phosphatidyl serine was present; however, if 12(S)-hydroxy-5,8,10,14-eicosatetraenoic acid or arachidonic acid, two lipid products formed in the cytoplasm of activated platelets, were present, no membrane-derived lipids were required for bryostatin-induced PKC activation.	Bryostatins	22-32	proline rich transmembrane protein 2	Homo sapiens	360-363
7679006-3	1993	However, in the presence of optimal concentrations of granulocyte colony-stimulating factor (G-CSF) or interleukin-6 (IL-6), TPA or bryostatin markedly elevated the number of colonies formed from the GM-CFC.	Bryostatins	132-142	interleukin 6	Homo sapiens	103-116
7679006-3	1993	However, in the presence of optimal concentrations of granulocyte colony-stimulating factor (G-CSF) or interleukin-6 (IL-6), TPA or bryostatin markedly elevated the number of colonies formed from the GM-CFC.	Bryostatins	132-142	interleukin 6	Homo sapiens	118-122
1877391-4	1991	It is possible that in some cases nPKC is the major mediator of the so-called PKC-activators, such as phorbol esters, mezerein, and bryostatins.	Bryostatins	132-143	protein kinase C gamma	Homo sapiens	35-38
8461005-3	1993	Both TPA and bryostatin 1 at 10 nM induced a rapid increase in membrane-associated PKC-alpha immunoreactivity which was sustained for 72 hours in TPA-treated cells, but was down-regulated within 24 hours in bryostatin-treated cells.	Bryostatins	13-23	protein kinase C alpha	Homo sapiens	83-92
1572907-8	1992	However, down-regulation of more than 90% of keratinocyte PKC activity by bryostatin pretreatment abrogated the induction of TGF-alpha mRNA in response to TPA without affecting the autoinductive response or EGF-stimulated tyrosine phosphorylation.	Bryostatins	74-84	proline rich transmembrane protein 2	Homo sapiens	58-61
1572907-8	1992	However, down-regulation of more than 90% of keratinocyte PKC activity by bryostatin pretreatment abrogated the induction of TGF-alpha mRNA in response to TPA without affecting the autoinductive response or EGF-stimulated tyrosine phosphorylation.	Bryostatins	74-84	transforming growth factor alpha	Homo sapiens	125-134
1737390-11	1992	Bryostatin, however, still caused loss of PKC-alpha isozyme and PKC activity from cytosolic and membrane fractions.	Bryostatins	0-10	protein kinase C alpha	Homo sapiens	42-51
1737390-11	1992	Bryostatin, however, still caused loss of PKC-alpha isozyme and PKC activity from cytosolic and membrane fractions.	Bryostatins	0-10	protein kinase C alpha	Homo sapiens	42-45
1834742-4	1991	Bryostatin (Bryo) and phorbol esters (e.g., 12-O-tetradecanoylphorbol 13-acetate (TPA] are PKC activators with somewhat different immunologic effects.	Bryostatins	0-10	protein kinase C alpha	Homo sapiens	91-94
1834742-4	1991	Bryostatin (Bryo) and phorbol esters (e.g., 12-O-tetradecanoylphorbol 13-acetate (TPA] are PKC activators with somewhat different immunologic effects.	Bryostatins	0-4	protein kinase C alpha	Homo sapiens	91-94
1904062-2	1991	The bryostatins, a family of macrocyclic lactones isolated from marine bryozoans, also bind to and active protein kinase C. However, they differ from TPA in the selectivity of their responses in that they behave either as agonists or antagonists of protein kinase C actions.	Bryostatins	4-15	plasminogen activator, tissue type	Rattus norvegicus	150-153
1904062-10	1991	Bryostatins 3 and 8 (each of which has an ester group in the R1 position, yet contains other structural modifications) are antagonists for TPA inhibition of GH4 cell proliferation like bryostatin 1.	Bryostatins	0-11	plasminogen activator, tissue type	Rattus norvegicus	139-142
1911215-0	1991	Phorbol ester and bryostatin effects on growth and the expression of oestrogen responsive and TGF-beta 1 genes in breast tumour cells.	Bryostatins	18-28	transforming growth factor beta 1	Homo sapiens	94-104
2049075-0	1991	Phorbol ester and bryostatin differentially regulate the hydrolysis of phosphatidylethanolamine in Ha-ras- and raf-oncogene-transformed NIH 3T3 cells.	Bryostatins	18-28	Harvey rat sarcoma virus oncogene	Mus musculus	99-105
2049075-0	1991	Phorbol ester and bryostatin differentially regulate the hydrolysis of phosphatidylethanolamine in Ha-ras- and raf-oncogene-transformed NIH 3T3 cells.	Bryostatins	18-28	zinc fingers and homeoboxes 2	Mus musculus	111-114
3257237-3	1988	Bryostatin greatly enhances efficiency of recombinant interleukin-2 in triggering development of in vivo primed CTL during in vitro incubation, thereby providing experimental evidence for the efficacious use of lower concentrations of recombinant interleukin-2 for in vivo tumor rejection studies.	Bryostatins	0-10	interleukin 2	Homo sapiens	54-67
2386956-10	1990	Furthermore, bryostatin induces secretion of GM-CSF by such cells in suspension and semisolid medium and also promotes clonal extinction of granulocyte-macrophage progenitors.	Bryostatins	13-23	colony stimulating factor 2	Homo sapiens	45-51
35102644-9	2022	Bryostatin, a natural anti-neoplastic reagent that activates PKC, induces YAP1/p73-mediated apoptosis in cancer cells.	Bryostatins	0-10	protein kinase C alpha	Homo sapiens	61-64
35102644-9	2022	Bryostatin, a natural anti-neoplastic reagent that activates PKC, induces YAP1/p73-mediated apoptosis in cancer cells.	Bryostatins	0-10	Yes1 associated transcriptional regulator	Homo sapiens	74-78
35102644-9	2022	Bryostatin, a natural anti-neoplastic reagent that activates PKC, induces YAP1/p73-mediated apoptosis in cancer cells.	Bryostatins	0-10	tumor protein p73	Homo sapiens	79-82
35102644-11	2022	Hence, bryostatin and other reagents that activate PKC are expected to control cancers with the dysfunction of the Hippo pathway.	Bryostatins	7-17	protein kinase C alpha	Homo sapiens	51-54
35222407-0	2022	Bryostatin Activates CAR T-Cell Antigen-Non-Specific Killing (CTAK), and CAR-T NK-Like Killing for Pre-B ALL, While Blocking Cytolysis of a Burkitt Lymphoma Cell Line.	Bryostatins	0-10	CXADR pseudogene 1	Homo sapiens	21-24
35222407-0	2022	Bryostatin Activates CAR T-Cell Antigen-Non-Specific Killing (CTAK), and CAR-T NK-Like Killing for Pre-B ALL, While Blocking Cytolysis of a Burkitt Lymphoma Cell Line.	Bryostatins	0-10	C-C motif chemokine ligand 27	Homo sapiens	62-66
35222407-7	2022	We confirmed the activity of bryostatin to increase CD22 expression on model cell lines.	Bryostatins	29-39	CD22 molecule	Homo sapiens	52-56
35222407-9	2022	Furthermore, bryostatin inhibited CAR-T mediated cytolysis of the Raji Burkitt lymphoma cell line.	Bryostatins	13-23	CXADR pseudogene 1	Homo sapiens	34-37
35222407-10	2022	Bryostatin increased the cytolysis by CD22 CAR-T for B-ALL cell lines by at least three mechanisms: 1) the previously reported increase in CD22 target cell numbers on the cell surface, 2) the induction of NK ligands, and 3) the induction of ligands that sensitize leukemia cells to activated T cell antigen-non-specific killing.	Bryostatins	0-10	CD22 molecule	Homo sapiens	38-42
35222407-10	2022	Bryostatin increased the cytolysis by CD22 CAR-T for B-ALL cell lines by at least three mechanisms: 1) the previously reported increase in CD22 target cell numbers on the cell surface, 2) the induction of NK ligands, and 3) the induction of ligands that sensitize leukemia cells to activated T cell antigen-non-specific killing.	Bryostatins	0-10	CXADR pseudogene 1	Homo sapiens	43-46
35222407-10	2022	Bryostatin increased the cytolysis by CD22 CAR-T for B-ALL cell lines by at least three mechanisms: 1) the previously reported increase in CD22 target cell numbers on the cell surface, 2) the induction of NK ligands, and 3) the induction of ligands that sensitize leukemia cells to activated T cell antigen-non-specific killing.	Bryostatins	0-10	CD22 molecule	Homo sapiens	139-143
3263149-8	1988	Bryostatin mimics the stimulatory action of IL-3 on W/Wv bone marrow.	Bryostatins	0-10	interleukin 3	Mus musculus	44-48
3263149-9	1988	Polyclonal antibody directed against murine IL-3 blocks the stimulatory effect of bryostatin on erythropoiesis.	Bryostatins	82-92	interleukin 3	Mus musculus	44-48
2210911-0	1990	Activation of T-cells by bryostatins: induction of the IL-2 receptor gene transcription and down-modulation of surface receptors.	Bryostatins	25-36	interleukin 2 receptor subunit beta	Homo sapiens	55-68
2210911-3	1990	Bryostatins bind and activate protein kinase C (PK-C), the cellular receptor for the phorbol ester, and elicit PK-D-dependent cellular functions.	Bryostatins	0-11	protein kinase D1	Homo sapiens	111-115
2210911-5	1990	Northern blot hybridization with a human IL-2R and an IL-2 cDNA showed that bryostatin 1 (bryo 1), like the phorbol ester, PMA, activates the IL-2R gene.	Bryostatins	76-86	interleukin 2 receptor subunit alpha	Homo sapiens	41-46
2210911-5	1990	Northern blot hybridization with a human IL-2R and an IL-2 cDNA showed that bryostatin 1 (bryo 1), like the phorbol ester, PMA, activates the IL-2R gene.	Bryostatins	76-86	interleukin 2	Homo sapiens	41-45
2210911-5	1990	Northern blot hybridization with a human IL-2R and an IL-2 cDNA showed that bryostatin 1 (bryo 1), like the phorbol ester, PMA, activates the IL-2R gene.	Bryostatins	76-86	interleukin 2 receptor subunit alpha	Homo sapiens	142-147
34779746-5	2021	Munc13-1 C1 shows higher conformational stability and less mobility along membrane with phorbol 13-acetate and bryostatin 1 than with resveratrol.	Bryostatins	111-121	unc-13 homolog A	Homo sapiens	0-8
2697470-7	1989	For example, bryostatin is a potent PKC activator that antagonizes phorbol ester-mediated tumor promotion, and mezerein is a second-stage tumor promoter that potently activates PKC.	Bryostatins	13-23	proline rich transmembrane protein 2	Homo sapiens	36-39
3257237-3	1988	Bryostatin greatly enhances efficiency of recombinant interleukin-2 in triggering development of in vivo primed CTL during in vitro incubation, thereby providing experimental evidence for the efficacious use of lower concentrations of recombinant interleukin-2 for in vivo tumor rejection studies.	Bryostatins	0-10	interleukin 2	Homo sapiens	247-260
3250479-0	1988	Bryostatin stimulation of human neutrophil luminol and DBA (lucigenin) chemiluminescence.	Bryostatins	0-10	loss of heterozygosity, 19, chromosomal region 1	Homo sapiens	32-58
3325877-0	1987	Bryostatin induces changes in protein kinase C location and activity without altering c-myc gene expression in human promyelocytic leukemia cells (HL-60).	Bryostatins	0-10	proline rich transmembrane protein 2	Homo sapiens	30-46
2442289-3	1987	The strict requirement for crosslinking of the TCR in exocytosis triggering could be bypassed by protein kinase C activators (phorbol esters or bryostatin I and II) acting in synergy with Ca2+ ionophores.	Bryostatins	144-154	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	47-50
3478136-4	1987	We report here that bryostatin 1 blocks phorbol ester action in Friend cells (clone PS 7), a second differentiating system.	Bryostatins	20-30	taste 2 receptor member 68 pseudogene	Homo sapiens	84-88
3325877-3	1987	In this study, we find that bryostatin, a macrocyclic lactone which does not induce differentiation of HL-60 cells but activates PK-C, mimics the effects of phorbol esters on protein phosphorylation and PK-C location.	Bryostatins	28-38	proline rich transmembrane protein 2	Homo sapiens	129-133
3325877-3	1987	In this study, we find that bryostatin, a macrocyclic lactone which does not induce differentiation of HL-60 cells but activates PK-C, mimics the effects of phorbol esters on protein phosphorylation and PK-C location.	Bryostatins	28-38	proline rich transmembrane protein 2	Homo sapiens	203-207
3325877-4	1987	Treatment of HL-60 cells with bryostatin stimulates phosphorylation of the surface transferrin receptor and in the cytoplasm of five proteins having the molecular weights of 17-43 kDa over the same time course as that stimulated by phorbol esters.	Bryostatins	30-40	transferrin	Homo sapiens	83-94
3325877-5	1987	Similarly, prolonged treatment with bryostatin, like that with phorbol esters, causes the loss of all cellular PK-C activity.	Bryostatins	36-46	proline rich transmembrane protein 2	Homo sapiens	111-115